Guidelines for vasodilator therapy of congestive heart failure in infants and children

Am Heart J. 1987 Apr;113(4):994-1005. doi: 10.1016/0002-8703(87)90062-7.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Captopril / adverse effects
  • Captopril / pharmacology
  • Captopril / therapeutic use
  • Child
  • Child, Preschool
  • Enalapril / adverse effects
  • Enalapril / pharmacology
  • Enalapril / therapeutic use
  • Heart Diseases / drug therapy
  • Heart Failure / drug therapy*
  • Heart Ventricles
  • Hemodynamics / drug effects
  • Humans
  • Hydralazine / adverse effects
  • Hydralazine / pharmacology
  • Hydralazine / therapeutic use
  • Infant
  • Nifedipine / adverse effects
  • Nifedipine / pharmacology
  • Nifedipine / therapeutic use
  • Nitroglycerin / adverse effects
  • Nitroglycerin / pharmacology
  • Nitroglycerin / therapeutic use
  • Nitroprusside / adverse effects
  • Nitroprusside / pharmacology
  • Nitroprusside / therapeutic use
  • Phentolamine / adverse effects
  • Phentolamine / pharmacology
  • Phentolamine / therapeutic use
  • Prazosin / adverse effects
  • Prazosin / pharmacology
  • Prazosin / therapeutic use
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*

Substances

  • Vasodilator Agents
  • Nitroprusside
  • Hydralazine
  • Enalapril
  • Captopril
  • Nitroglycerin
  • Nifedipine
  • Prazosin
  • Phentolamine